![Patrick G. Harran](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrick G. Harran
Fondateur chez Joyant Pharmaceuticals, Inc.
Postes actifs de Patrick G. Harran
Sociétés | Poste | Début | Fin |
---|---|---|---|
Joyant Pharmaceuticals, Inc.
![]() Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Fondateur | 16/04/2010 | - |
Corporate Officer/Principal | 01/11/2004 | 16/04/2010 | |
Alfred P. Sloan Foundation
![]() Alfred P. Sloan Foundation Miscellaneous Commercial ServicesCommercial Services Alfred P Sloan Foundation operates a non-profit organization. Its programs and interests are divided into five main areas as science & technology, standard of living & economic performance, education &careers in science & technology, selected national issues and the civic program. The foundation was established in 1934 and is headquartered in New York | Corporate Officer/Principal | 20/04/2010 | - |
Historique de carrière de Patrick G. Harran
Anciens postes connus de Patrick G. Harran
Sociétés | Poste | Début | Fin |
---|---|---|---|
Diazon Pharmaceuticals, Inc.
![]() Diazon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diazon Pharmaceuticals, Inc. engages in the development of the onco-therapeutic DZ-2384 that targets a proven therapeutic pathway in oncology. The company was founded by Anne Roulston, Gordon Shore and Patrick Harran in 2013 and is headquartered in Montreal, Canada. | Fondateur | 01/01/2013 | - |
The University of Texas at Austin | Corporate Officer/Principal | - | - |
Formation de Patrick G. Harran
Yale University | Doctorate Degree |
Skidmore College | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Canada | 2 |
Opérationnelle
Corporate Officer/Principal | 3 |
Founder | 2 |
Doctorate Degree | 1 |
Sectorielle
Consumer Services | 4 |
Health Technology | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Joyant Pharmaceuticals, Inc.
![]() Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
Alfred P. Sloan Foundation
![]() Alfred P. Sloan Foundation Miscellaneous Commercial ServicesCommercial Services Alfred P Sloan Foundation operates a non-profit organization. Its programs and interests are divided into five main areas as science & technology, standard of living & economic performance, education &careers in science & technology, selected national issues and the civic program. The foundation was established in 1934 and is headquartered in New York | Commercial Services |
Diazon Pharmaceuticals, Inc.
![]() Diazon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diazon Pharmaceuticals, Inc. engages in the development of the onco-therapeutic DZ-2384 that targets a proven therapeutic pathway in oncology. The company was founded by Anne Roulston, Gordon Shore and Patrick Harran in 2013 and is headquartered in Montreal, Canada. | Health Technology |
- Bourse
- Insiders
- Patrick G. Harran
- Expérience